These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 22260026

  • 1. [Design, synthesis and activity of a new type of influenza virus N1 neuraminidase inhibitors].
    Yang F, Jin L, Huang NY, Chen F, Luo HJ, Chen JF.
    Yao Xue Xue Bao; 2011 Nov; 46(11):1344-8. PubMed ID: 22260026
    [Abstract] [Full Text] [Related]

  • 2. Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase.
    Xie Y, Xu D, Huang B, Ma X, Qi W, Shi F, Liu X, Zhang Y, Xu W.
    J Med Chem; 2014 Oct 23; 57(20):8445-58. PubMed ID: 25255388
    [Abstract] [Full Text] [Related]

  • 3. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA).
    Mitrasinovic PM.
    Biophys Chem; 2009 Mar 23; 140(1-3):35-8. PubMed ID: 19117662
    [Abstract] [Full Text] [Related]

  • 4. Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus.
    Park JW, Jo WH.
    Eur J Med Chem; 2010 Feb 23; 45(2):536-41. PubMed ID: 19914748
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Further discovery of caffeic acid derivatives as novel influenza neuraminidase inhibitors.
    Xie Y, Huang B, Yu K, Xu W.
    Bioorg Med Chem; 2013 Dec 15; 21(24):7715-23. PubMed ID: 24262883
    [Abstract] [Full Text] [Related]

  • 7. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus.
    Du QS, Wang SQ, Chou KC.
    Biochem Biophys Res Commun; 2007 Oct 19; 362(2):525-31. PubMed ID: 17707775
    [Abstract] [Full Text] [Related]

  • 8. Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant.
    García-Sosa AT, Sild S, Maran U.
    J Chem Inf Model; 2008 Oct 19; 48(10):2074-80. PubMed ID: 18847186
    [Abstract] [Full Text] [Related]

  • 9. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q, Yang J, Liang K, Feng L, Li S, Wan J, Xu X, Yang G, Liu D, Yang S.
    J Chem Inf Model; 2008 Sep 19; 48(9):1802-12. PubMed ID: 18707092
    [Abstract] [Full Text] [Related]

  • 10. Comment on "Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)".
    Rungrotmongkol T, Malaisree M, Udommaneethanakit T, Hannongbua S.
    Biophys Chem; 2009 Apr 19; 141(1):131-2; author reply 133. PubMed ID: 19231807
    [No Abstract] [Full Text] [Related]

  • 11. Caffeic acid derivatives: a new type of influenza neuraminidase inhibitors.
    Xie Y, Huang B, Yu K, Shi F, Liu T, Xu W.
    Bioorg Med Chem Lett; 2013 Jun 15; 23(12):3556-60. PubMed ID: 23664211
    [Abstract] [Full Text] [Related]

  • 12. Design, synthesis, and biological activity of thiazole derivatives as novel influenza neuraminidase inhibitors.
    Liu Y, Zhang L, Gong J, Fang H, Liu A, Du G, Xu W.
    J Enzyme Inhib Med Chem; 2011 Aug 15; 26(4):506-13. PubMed ID: 21143042
    [Abstract] [Full Text] [Related]

  • 13. Virtual screening pipeline and ligand modelling for H5N1 neuraminidase.
    D'Ursi P, Chiappori F, Merelli I, Cozzi P, Rovida E, Milanesi L.
    Biochem Biophys Res Commun; 2009 Jun 12; 383(4):445-9. PubMed ID: 19371724
    [Abstract] [Full Text] [Related]

  • 14. Design, synthesis and biological evaluation of novel oseltamivir derivatives as potent neuraminidase inhibitors.
    Wang Z, Cheng LP, Zhang XH, Pang W, Li L, Zhao JL.
    Bioorg Med Chem Lett; 2017 Dec 15; 27(24):5429-5435. PubMed ID: 29141777
    [Abstract] [Full Text] [Related]

  • 15. Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation.
    Malaisree M, Rungrotmongkol T, Nunthaboot N, Aruksakunwong O, Intharathep P, Decha P, Sompornpisut P, Hannongbua S.
    Amino Acids; 2009 Oct 15; 37(4):725-32. PubMed ID: 19002747
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A.
    Wang K, Lei Z, Zhao L, Chen B, Yang F, Liu K, Zhu H, Zhao H, Cao R, Zhang K, Tian Y.
    Eur J Med Chem; 2020 Jan 01; 185():111841. PubMed ID: 31708183
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and Biological Evaluation of NH2-Sulfonyl Oseltamivir Analogues as Influenza Neuraminidase Inhibitors.
    Hu Y, Chen B, Lei Z, Zhao H, Zhu H, Quan P, Tian Y.
    Molecules; 2019 Jun 10; 24(11):. PubMed ID: 31185617
    [Abstract] [Full Text] [Related]

  • 18. Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases.
    Wang SQ, Du QS, Chou KC.
    Biochem Biophys Res Commun; 2007 Mar 16; 354(3):634-40. PubMed ID: 17266937
    [Abstract] [Full Text] [Related]

  • 19. Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity.
    Shie JJ, Fang JM, Wang SY, Tsai KC, Cheng YS, Yang AS, Hsiao SC, Su CY, Wong CH.
    J Am Chem Soc; 2007 Oct 03; 129(39):11892-3. PubMed ID: 17850083
    [No Abstract] [Full Text] [Related]

  • 20. The hydrophobic side chain of oseltamivir influences type A subtype selectivity of neuraminidase inhibitors.
    Lin X, Qin-Hua C, Peng L, Chun-Lei L, Guang-De Y.
    Chem Biol Drug Des; 2018 Jan 03; 91(1):105-115. PubMed ID: 28646621
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.